药智数据显示，在2016年至2025上半年，国内公立医疗机构创新药销售额排名中（本文所讨论的药物范畴均限定为创新药；即便相关药物专利已过期且已 有仿制药上市，销售额统计仍仅针对其原研创新药），辉瑞（晖致）的阿托伐他汀钙片累计销售额高达492.7亿元，稳居近十年中国创新药市场之首，成 为名副其实的"销量冠军"。 01 "王者逻辑" 图片来源：药智数据 从年度销售走势来看，2016年至2019年是其黄金成长期，销售额从56.12亿元稳步攀升至68.54亿元，2018年更是创下74.05亿元的年度峰值，成为TOP10榜 单中唯一单年销售额突破70亿元的产品，尽显"王者"姿态。2020年，受国家带量采购政策影响，其销售额回落至38.47亿元。但凭借强大的临床刚需支 撑，此后几年（2021-2024年）销售额稳定在43亿—44亿元区间。2025年上半年已实现23.75亿元的销售额，药智数据预测其全年销售额有望突破41亿元， 这也印证了这款产品在政策调整后的市场韧性。 阿托伐他汀钙片（辉瑞）国内公立医疗机构年度销售额 图片来源：药智数据 一款药品能够登上"十年销冠"宝座，绝非偶然，是临床需求、产品优势以及特定的市场环境共 ...

Core Insights - Mingyu Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as joint sponsors [1] - The company, established in 2018, is a biotechnology innovator with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody (bsAb) [1] - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 in clinical stages, and expects to generate revenue from its autoimmune projects soon [1] - The oncology projects focus on advancing ADC monotherapy for later-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to innovate first-line cancer treatment [1]

Core Insights - Mingyu Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities acting as joint sponsors [1] - The company, established in 2018, is a biotechnology innovation enterprise with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb) [1] - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 in clinical stages, and expects to generate revenue from its autoimmune projects soon [1] - The oncology projects focus on advancing ADC monotherapy for later-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to innovate first-line cancer treatment [1]